论文部分内容阅读
目的 观察新型双膦酸盐BM2 10 95 5 (Ibandronate)防治卵巢切除大鼠骨量丢失的效果。方法 取 10～ 12月龄SD大鼠 40只 ,分为 4组 ,实验组大鼠作双侧卵巢切除 3个月后 ,再给予BM 2 10 95 5 0 .5mg·kg-1·d-1,用药 3个月。设骨质疏松动物模型 (OP模型 )对照组 ,假手术对照组及OP模型 +BM 2 10 95 5及尼尔雌醇组作比较。结果 骨干重、灰重和钙含量及股骨骨密度OP模型对照组低于假手术对照组 ,BM2 10 95 5及尼尔雌醇两用药组高于OP模型对照组且均有显著性意义 (P<0 .0 2或P <0 .0 0 1) ;全身骨密度水平BM 2 10 95 5及尼尔雌醇两用药组较OP模型对照组分别增加8.7%及 0 .9% ;椎骨、胫骨骨小梁面积BM2 10 95 5及尼尔雌醇用药组均高于OP模型对照组且均有显著性意义 (P <0 .0 1) ;尿钙与肌酐 (Ca/Cr)比值BM 2 10 95 5及尼尔雌醇用药组低于OP模型对照组均有显著性意义 (P <0 .0 0 1) ,尿羟脯氨酸与肌酐 (HOP/Cr)比值及血清碱性磷酸酶 (ALP)的水平 ,BM 2 10 95 5及尼尔雌醇用药组较OP模型对照组均有下降趋势。结论 SD大鼠卵巢切除 3个月后出现明显的骨质疏松 ,BM2 10 95 5对卵巢切除骨质疏松动物模型大鼠骨量的丢失有显著治疗作用。
Objective To observe the effect of a novel bisphosphonate BM2 10 95 5 (Ibandronate) on prevention and treatment of bone loss in ovariectomized rats. Methods 40 SD rats aged 10 ~ 12 months were divided into 4 groups. After 3 months of bilateral ovariectomy in the experimental group, BM 2 10 95 50.5 mg · kg -1 · d -1 , Medication 3 months. Osteoporosis animal model (OP model) control group, sham operation control group and OP model + BM 2 10 95 5 and nilestriol group for comparison. Results The weight, weight, calcium content and femoral bone mineral density of the OP model control group were lower than those of the sham-operation control group, BM2 10 955 and nilestriol were higher than the OP model control group (P <0. 02 or P <0. 01). The BMD of BM 2 10 95 5 and nilestriol increased by 8.7% and 0.9% respectively compared with the OP model control group. The vertebra, tibia Trabecular bone area BM2 10 95 5 and nilestriol treatment group were higher than the OP model control group and have significant significance (P <0.01); urinary calcium and creatinine (Ca / Cr ratio BM 2 10 (P <0.01), the ratio of urinary hydroxyproline to creatinine (HOP / Cr) and serum alkaline phosphatase ALP) levels, BM 2 10 95 5 and nilestriol administration group compared with the OP model control group have a downward trend. Conclusions Osteoporosis was observed 3 months after ovariectomy in SD rats, and BM2 10 955 had a significant therapeutic effect on the loss of bone mass in ovariectomized animal models of osteoporosis.